Technology

1p deletions involving the CDKN2C gene are important markers for risk stratification in multiple myeloma. While FISH can identify many 1p deletions, detecting bi-allelic deletions involving loss of both gene copies may be challenging. PlasmaSEQ provides comprehensive genomic profiling that can help identify these alterations with enhanced resolution.

TP53 alterations are key determinants of risk stratification in multiple myeloma. PlasmaSEQ offers high-resolution analysis, enabling the detection of small multi-exonic deletions as well as single nucleotide variants within a single comprehensive assay, providing genomic insights beyond conventional approaches.

The precise breakpoint of IgH rearrangements in translocations such as t(4;14) and t(14;16) may have prognostic significance in multiple myeloma. PlasmaSEQ provides breakpoint-level characterization for each patient, generating valuable genomic information that can support research efforts and contribute to the design of future clinical studies.

As immunotherapy strategies continue to evolve, comprehensive assessment of clinically relevant targets such as BCMA, GPRC5D, and APRIL becomes increasingly important. PlasmaSEQ V2 incorporates these targets into a single assay and is designed to detect genomic abnormalities even in samples with low plasma cell content.